fda glp-1 warning letters september 2025 news Beyond the Headlines: to Compounders The FDA sent a warning

For 503B outsourcing facilities, no equivalent safe harbor appears to apply, and enforcement grace periods that had been in place through early 2026 are expiring, leaving bulk compounders of GLP-1s in a substantially more precarious legal position

Domestic pharmaceutical companies are also entering the incretin drug development field, intensifying competition and accelerating product innovation in the region

F., Hu, M

Marwin Barro

The purpose of the parent study was to examine pharmacodynamic and pharmacokinetic parameters of oral, smoked, and vaporized cannabis in occasional and frequent users

For the past four years, weve been recording episodes with video, including some filmed at the iconic NBC Universal Stamford Studios